HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Market News Market Pulse Stocks News ETF News Crypto News

Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

By TheFly | March 11, 2026, 6:00 AM
XENE
-4.37%
Xenon Pharmaceuticals Inc

The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Blair acted as joint book running managers for the offering.

Claim 70% Off TipRanks Premium

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Mentioned In This Article

XENE
-4.37%
Xenon Pharmaceuticals Inc

Latest News

Apr-19
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting XENE GlobeNewswire
Apr-15
Xenon to Present at Upcoming Investor Conferences XENE GlobeNewswire
Apr-07
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting XENE GlobeNewswire
Mar-12
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares XENE GlobeNewswire
Mar-11
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00 XENE TipRanks
Mar-10
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering XENE GlobeNewswire
Mar-10
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study XENE Zacks
Mar-10
Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy XENE BioPharma Dive
Mar-09
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today XENE +49.64% 24/7 Wall St.
Mar-09
Xenon Smashes Its Previous Record High On 'Unprecedented' Results. Is A Buyout Next? XENE +49.64% Investor's Business Daily
Mar-09
Xenon Pharmaceuticals Announces Proposed Public Offering XENE +49.64% GlobeNewswire
Mar-09
Analysts tout market potential of Xenons epilepsy drug on Phase III win XENE +49.64% Clinical Trials Arena
Mar-09
What's Going On With Biohaven Stock On Monday? XENE +49.64% Benzinga
Mar-09
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures XENE +49.64% Benzinga
Mar-09
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) XENE +49.64% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)